Latest Conference Coverage

Hideki Garren, MD, PhD: Past and Future Ocrelizumab Analyses

The group medical director of neuroscience at Genentech discussed the history of a well-known therapy for multiple sclerosis: ocrelizumab (Ocrevus).

Vagus Nerve Stimulation Improves Headache, Migraine Pain

A non-invasive vagus nerve stimulation therapy significantly improved pain-free rates compared with a sham device for patients with episodic cluster headache and migraines.

Teriflunomide Improves Patient Satisfaction in Teri-PRO, TENERE Trials

The disease-modifying therapy showed significant improvements in 4 TSQM measures for patients with relapsing multiple sclerosis.

Lilyana Amezcua, MD: Better Understanding MS in the Hispanic Community

The associate professor of clinical neurology spoke about the need to understand modifiable social and cultural factors that could impact disease severity and progression.

Gregory Day, MD, MSc: The Challenge of Alzheimer Diagnosis

The clinical director of the Anti-NMDA Receptor Encephalitis Foundation spoke about the insidiousness of AD and the need for diagnosis earlier in disease progression.

NP001 Fails to Meet Primary, Secondary Endpoints in ALS Trial

The announcement was discouraging to many, as only 2 agents for ALS have been granted FDA approval in as many decades.

Alberto Espay, MD, MSc: Modifying Thought About Parkinson Disease

The UC Health professor of neurology argued that with the current view on Parkinson disease, the field is missing the mark for disease-modifying interventions.

Ralph Kern, MD, MHSc: The State of Therapies for ALS

The chief medical officer and chief operating officer of Brainstorm Cell Therapeutics spoke about a host of topics related to the treatment of amyotrophic lateral sclerosis.

Eptinezumab Migraine Prevention Sustained in 12-Month Analysis

More than two-thirds of patients treated with intravenous infusions of the CGRP inhibitor eptinezumab had an average 50% reduction in migraines.

IncobotulinumtoxinA Successful in Treating Sialorrhea in Parkinson, Other Neurological Conditions

Study findings revealed statistically significant results at week 4 for the 100-U dose compared to placebo. The 75-U dose, while effective, did not achieve statistical significance.

Siponimod Reduces Disability Progression in Secondary Progressive Multiple Sclerosis

The data from the phase III EXPAND study indicated to the researchers that this risk reduction obtained with siponimod was substantially isolated from MS relapse.

Erenumab Displays Success in Patients Who Failed 2 or More Preventative Migraine Treatments

The calcitonin gene-related peptide inhibitor lowered monthly migraine days by ≥50% in 30.3% of patients compared to 13.7% on placebo.